Resveratrol in experimental Alzheimer's disease models: A systematic review of preclinical studies

source extracted confidence: high 2026-04-09
#alzheimer-disease #amyloid-beta-peptides #animals #anti-inflammatory-agents #antioxidants

Resveratrol in experimental Alzheimer's disease models: A systematic review of preclinical studies

Chen et al., 2019 | Pharmacol Res | Systematic Review

Citation

Chen Jia-Yue, Zhu Qi, ... Lu Jia-Hong. Resveratrol in experimental Alzheimer's disease models: A systematic review of preclinical studies. Pharmacol Res. 2019-Dec;150:104476. doi:10.1016/j.phrs.2019.104476

Abstract

Alzheimer's disease (AD) is a progressive dementia caused by degeneration of the central nervous system with a high incidence in the elderly. Resveratrol is a natural compound contained in a wide range of plant species, including grapes. Recent studies have shown positive effects of resveratrol in animal models of AD; however, whether these results justify clinical trials is uncertain. Furthermore, there are multiple theories about the mechanism(s) by which resveratrol works and knowing how it works can suggest targets for future drug development. So far, systematic evaluation of both of these aspects is lacking. In this study, we selected 19 studies describing the efficacy of resveratrol in rodent AD models by electronic and manual retrieval. The method quality of the study were analyzed by the SYRCLE's risk of bias tool and the experimental data were retrieved and meta-analyzed using forest plot. Analysis of these studies demonstrates the consistent neuroprotective effects of resveratrol in AD models and offers insights into the possible pharmacological mechanisms. This information eliminates the bias of each study, providing supporting evidence for the implementation of clinical trials. However, the limits of studies were also noticed: low method quality, lack of sample size calculation and high risks of bias.

Key Findings

However, the limits of studies were also noticed: low method quality, lack of sample size calculation and high risks of bias.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 19
Age Range See abstract
Condition See abstract

MeSH Terms

  • Alzheimer Disease
  • Amyloid beta-Peptides
  • Animals
  • Anti-Inflammatory Agents
  • Antioxidants
  • Disease Models, Animal
  • Neuroprotective Agents
  • Resveratrol
  • tau Proteins

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Journal Article, Research Support, Non-U.S. Gov't, Systematic Review
  • Vertical: resveratrol

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09